numares HEALTH at a glance

numares develops and markets products for clinical diagnostics and life science research. Medical and diagnostic tests with CE marking for the use in clinical practice, e.g. for diagnosis and therapy monitoring.


numares AG is headquartered in the Biopark Regensburg, Germany.


Since 2014, numares has been a Aktiengesellschaft.

The majority shareholder in numares AG is the SHS Gesellschaft für Beteiligungsmanagement in Tübingen, Germany.

Company milestones

The company was launched in April 2004 as a "spin-off" of the Institute of Biophysics at the University of Regensburg with a new method for the routine determination of lipoproteins using nuclear magnetic resonance spectroscopy (NMR).

Today, the focus is on the development of in vitro diagnostic tests and test systems for Clinical Diagnostics and Life Science Research, based on the use of complex metabolic data and numares' proprietary Magnetic Group Signaling (MGS®) technology.

2017Launch of  AXINON® renalTX-SCORE®-U100: first metabolomics IVD test for allograft rejection diagnostics after kidney transplantation
2017Collaboration with Oxford University on the development of Multiple Sclerosis diagnostic test
2017Launch of RUO test AXINON® insightLP-S50TM for lipoprotein composition analysis
20161,000.000 performed analyses
2016numares completes another financing round
2015Launch of CE-marked IVD tests AXINON® lipoFIT®-S100 and AXINON® lipoFIT®-S100-400 for NMR-based lipoprotein profiling
2014600.000 performed analyses
2014Successful completion of studies on kidney transplantation and prostate cancer
2014numares GmbH becomes numares AG
2014Cooperation with a german laboratory network: commissioning of a test system for lipoprotein profiling
2013200.000 performed analyses
2013Bulk order from a U.S. laboratory chain: installation of multiple test systems for lipoprotein profiling
2013Successful certification of numares according to EN ISO 13485: 2012 as a manufacturer of in-vitro diagnostics (IVD)
2012Expansion of technical capacity by 400 MHz and 600 MHz NMR-high throughput platform
2010100.000 performed analyses
2009Certification as per EN ISO 13485:2003
as off  2005Measurements within large studies such as GRAPHIC and KORA
2004First patent for the determination of lipoproteins in body fluids (lipoprotein profiling)